K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Nature

Volumn 503, Issue 7477, 2013, Pages 548-551

  Ostrem, Jonathan M ^a   Peters, Ulf ^a   Sos, Martin L ^a   Wells, James A ^b   Shokat, Kevan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GUANOSINE DIPHOSPHATE; K RAS PROTEIN; PROTEIN INHIBITOR;

CANCER; CHEMICAL BINDING; CRYSTALLOGRAPHY; ENZYME ACTIVITY; HYDROLYSIS; INHIBITOR; LESION; MUTATION; PROTEIN;

ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; HYDROLYSIS; IC 50; LIMIT OF DETECTION; MASS SPECTROMETRY; METAL BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; SOMATIC MUTATION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; APOPTOSIS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; DRUG DISCOVERY; GENES, RAS; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MUTANT PROTEINS; ONCOGENE PROTEIN P21(RAS); RAF KINASES; STATIC ELECTRICITY; SUBSTRATE SPECIFICITY;

EID: 84888639050     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12796     Document Type: Article

References (30)

1. Slebos, R. J. C. et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 323, 561-565 (1990).
2. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
3. Lievre, A. et al. KRASmutationstatus is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
4. John, J. et al. Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. Biochemistry 29, 6058-6065 (1990).
5. Gibbs, J. B., Sigal, I. S., Poe, M. &Scolnick, E. M. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl Acad. Sci. USA 81, 5704-5708 (1984).
6. Trahey, M. &McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238, 542-545 (1987).
7. Scherer, A. et al. Crystallization and preliminary X-ray analysis of the human c-H-ras-oncogene product p21 complexed with GTP analogues. J. Mol. Biol. 206, 257-259 (1989).
8. Erlanson, D. A. et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97, 9367-9372 (2000).
9. Burlingame, M. A., Tom, C. T. M. B. &Renslo, A. R. Simple one-pot synthesis of disulfide fragments for use in disulfide-exchange screening. ACS Comb. Sci. 13, 205-208 (2011).
10. Sadowsky, J. D. et al. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl Acad. Sci. USA 108, 6056-6061 (2011).
11. Forbes, S. A. et al. The catalogue of somatic mutations in cancer (COSMIC). Curr. Protoc. Hum. Genet. 57, 10. 11. 1-10. 11. 26 (2008).
12. Bar-Sagi, D. A Ras by any other name. Mol. Cell. Biol. 21, 1441-1443 (2001).
13. Milburn, M. V. et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939-945 (1990).
14. Taveras, A. G. et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. 5, 125-133 (1997).
15. Naven, R. T., Kantesaria, S., Nadanaciva, S., Schroeter, T. &Leach, K. L. High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds. Toxicol. Rev. 2, 235-244 (2013).
16. John, J. et al. Kinetic andstructural analysis of theMg21-bindingsite of the guanine nucleotide-binding protein p21H-ras. J. Biol. Chem. 268, 923-929 (1993).
17. Feig, L. A. &Cooper, G. M. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol. 8, 3235-3243 (1988).
18. Farnsworth, C. L. &Feig, L. A. Dominant inhibitory mutations in the Mg21-binding site of RasH prevent its activation by GTP. Mol. Cell. Biol. 11, 4822-4829 (1981).
19. Hall, B. E., Yang, S. S., Boriack-Sjodin, P. A., Kuriyan, J. &Bar-Sagi, D. Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange. J. Biol. Chem. 276, 27629-27637 (2001).
20. Pai, E. F. et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209-214 (1989).
21. Sung, Y. -J., Carter, M., Zhong, J. -M. &Hwang, Y. -W. Mutagenesis of the H-ras p21 at glycine-60 residue disrupts GTP-induced conformational change. Biochemistry 34, 3470-3477 (1995).
22. Hwang, M. -C. C., Sung, Y. -J. &Hwang, Y. -W. The differential effects of the Gly-60 to Ala mutation on the interaction of H-Ras p21 with different downstream targets. J. Biol. Chem. 271, 8196-8202 (1996).
23. Sunaga, N. et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer Ther. 10, 336-346 (2011).
24. Barbie, D. A. et al. SystematicRNAinterference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
25. Peyroche, A. et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex. Mol. Cell 3, 275-285 (1999).
26. Nishimura, A. et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl Acad. Sci. USA 107, 13666-13671 (2010).
27. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299-5304 (2012).
28. Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. 124, 6244-6247 (2012).
29. Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blockingtheRas-effector interaction. Proc. Natl Acad. Sci. USA 110, 8182-8187 (2013).
30. Ahmadian, M. R. et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc. Natl Acad. Sci. USA 96, 7065-7070 (1999).